
リドカイン (注射液中) Lidocaine (in parenteral solution)

日本薬局方におけるカラム選定条件は ,「リドカイン , 内標準物質の順に溶出し , その分離度が 6 以上あるものを用いる」と定められています . CAPCELL PAK C_{18} MGII では , 分離度が 7.8 でした .

The Japanese Pharmacopoeia requires a column to elute compounds in the order of lidocain and its internal standard, with a resolution value of 6 or greater between the two compounds. CAPCELL PAK C_{18} MGII showed a resolution of 7.8.



H, O

2

- 1. リドカイン (2 mg/mL) Lidocaine (M.W. 234.3)
- ベンゾフェノン (I.S.) (50 µg/mL)
 Benzophenone (I.S.) (M.W. 182.2)

[HPLC Conditions]

Column : CAPCELL PAK C₁₈ MGII S5 ; 4.6 mm i.d. x 150 mm

Mobile phase : {20 mmol/L KH₂PO₄ (adjusted at pH 3.0 with phosphoric acid) /

 $CH_3CN = 55 / 45$ } / Sodium dodecyl sulfate = 1000 mL / 2.88 g

1

Flow rate : 1.8 mL/minTemperature : $25 \, ^{\circ}\text{C}$

Detection : UV 254 nm

Inj. vol. : $5 \mu L$

Sample dissolved in : 0.5 mL of 1 mol/mL HCl was added to 100 mg of lidocaine. A few

milliliters of 1 mmol/L HCl was further added so that the compound be completely dissolved. 10 mL of the internal standard solution (benzophenone in methanol, 250 μ g/mL) was added to the solution. The solution was diluted to 50 mL in a volumetric flask

with 1 mmol/L HCl.

% 1 μ g/mL = 1 ppm